Zydus Lifesciences Ltd.

BSE: 532321 | NSE: ZYDUSLIFE

Mid Cap | Pharmaceuticals & Drugs

928.85

-7.50 (-0.80%)

< Home < Back

Zydus Lifesciences informs about press release

Date: 04-08-2022

Zydus Lifesciences has informed about press releases dated August 4, 2022 titled 'Zydus receives final approval from the USFDA for Ivermectin Cream' and 'Zydus receives final approval from the USFDA for Empagliflozin Tablets'.

The above information is a part of company’s filings submitted to BSE.